Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Venanprubart (LY3361237) in Healthy Subjects
NCT03695198Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2018
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of venanprubart in systemic lupus erythematosus (SLE), psoriasis and rheumatoid arthritis (RA) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Oct 2018; status: completed.
02
Drugs
venanprubart
03
Conditions
systemic lupus erythematosus (SLE)psoriasisrheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03695198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03695198.